Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

563
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
563
Assessment of apical pulse01:17

Assessment of apical pulse

924
Assessing the Apical Pulse
Assessing the apical pulse is a critical nursing procedure, particularly indicated for:
924
Assessment of apical radial pulse01:25

Assessment of apical radial pulse

740
Apical-Radial (A-R) Pulse Assessment
The A-R pulse assessment involves simultaneous evaluation of the apical and radial pulses. When the apical and radial pulse rates vary, this assessment helps identify a pulse deficit.
Pre-Procedural Preparation
740

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lp(a): A potentially modifiable cardiovascular risk factor.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Assessing pharmacists' knowledge and practices involving dietary supplement omega-3 fatty acids.

Journal of clinical lipidology·2025
Same author

Drug Interactions With Excessive Daytime Sleepiness Treatments.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2025
Same author

A narrative review of drugs targeting inflammation in vascular disease.

Postgraduate medicine·2025
Same author

Climbing to the Summit of Guideline Directed Therapy of Heart Failure:A Slippery Slope.

The American journal of cardiology·2025
Same author

A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2024

Related Experiment Video

Updated: Jun 29, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

Elevated Lp(a): Guidance for Identifying and Managing Patients.

Daniel E Hilleman1, James L Vacek2, James M Backes3

  • 1From the Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska.

Southern Medical Journal
|April 3, 2024
PubMed
Summary

Lipoprotein(a) (Lp(a)) is a key genetic risk factor for cardiovascular disease. While current treatments offer limited Lp(a) reduction, new RNA-based therapies show promise for significant Lp(a) lowering.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.3K

Related Experiment Videos

Last Updated: Jun 29, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.3K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Pharmacology

Background:

  • Lipoprotein(a) (Lp(a)) is a lipoprotein particle independently linked to atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis.
  • Elevated Lp(a) is a common genetic dyslipidemia, affecting about 20% of the population, and is associated with increased ASCVD risk.
  • Lp(a) is primarily genetic and minimally impacted by lifestyle changes, necessitating targeted therapeutic strategies.

Purpose of the Study:

  • To review the role of Lp(a) as a causal risk factor for ASCVD.
  • To discuss current therapeutic options and their limitations in managing elevated Lp(a).
  • To highlight the potential of novel RNA-based therapies for Lp(a) reduction.

Main Methods:

  • Literature review of Lp(a) pathophysiology, epidemiology, and therapeutic approaches.
  • Analysis of current lipid-lowering drugs and their effect on Lp(a) levels.
  • Examination of investigational RNA-based therapies targeting Lp(a).

Main Results:

  • Lp(a) levels ≥125 nmol/L are associated with heightened ASCVD risk, though this threshold lacks universal acceptance.
  • Existing therapies like PCSK9 inhibitors offer only moderate Lp(a) reductions and are not specifically indicated for its treatment.
  • Four investigational RNA-based agents demonstrate significant Lp(a) reduction (70-100%), with two in outcomes trials.

Conclusions:

  • Novel RNA-based therapies represent a promising advancement in managing elevated Lp(a) and reducing ASCVD risk.
  • Until these therapies are widely available and proven effective in outcomes trials, intensive management of traditional ASCVD risk factors remains crucial.